Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-09-29 AccNo: 0001493152-26-044792 Size: 383 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Item 9.01: Financial Statements and Exhibits
2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout in OVATION
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to dateNo cytokine release syndrome, systemic toxicities or serious